

Special Issue

Prevalence and Antibiotic Resistance of *Mycobacterium tuberculosis*

Message from the Guest Editor

Tuberculosis (TB) is a communicable infectious disease caused by *Mycobacterium tuberculosis*. Drug resistance, especially multidrug resistance (MDR), is an important risk factor in TB treatment failure and death. Monitoring and understanding *Mycobacterium tuberculosis* distribution, pathogenesis, and antimicrobial resistance is critical in developing new strategies to control this bacterium more efficiently. For this Special Issue, we welcome contributions on the prevalence and antimicrobial resistance of *Mycobacterium tuberculosis*.

Guest Editor

Prof. Dr. Chongguang Yang

School of Public Health (Shenzhen), Sun Yat-sen University, No. 135, Xingang Xi Road, Guangzhou 510275, China

Deadline for manuscript submissions

closed (20 August 2025)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/233231

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)